- Home
- BIAF vs PRTG Comparison
BIAF vs PRTG Comparison
Compare BIAF & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- PRTG
- Stock Information
- Founded
- BIAF 2014
- PRTG 1973
- Country
- BIAF United States
- PRTG British Virgin Islands
- Employees
- BIAF N/A
- PRTG N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PRTG Oil & Gas Production
- Sector
- BIAF Health Care
- PRTG Energy
- Exchange
- BIAF Nasdaq
- PRTG Nasdaq
- Market Cap
- BIAF 12.2M
- PRTG 11.1M
- IPO Year
- BIAF 2022
- PRTG N/A
- Fundamental
- Price
- BIAF $0.49
- PRTG $9.00
- Analyst Decision
- BIAF Hold
- PRTG
- Analyst Count
- BIAF 1
- PRTG 0
- Target Price
- BIAF N/A
- PRTG N/A
- AVG Volume (30 Days)
- BIAF 28.5M
- PRTG 3.7M
- Earning Date
- BIAF 05-14-2025
- PRTG 04-29-2025
- Dividend Yield
- BIAF N/A
- PRTG N/A
- EPS Growth
- BIAF N/A
- PRTG N/A
- EPS
- BIAF N/A
- PRTG N/A
- Revenue
- BIAF $9,362,022.00
- PRTG N/A
- Revenue This Year
- BIAF N/A
- PRTG N/A
- Revenue Next Year
- BIAF $19.99
- PRTG N/A
- P/E Ratio
- BIAF N/A
- PRTG N/A
- Revenue Growth
- BIAF 269.68
- PRTG N/A
- 52 Week Low
- BIAF $0.24
- PRTG $2.10
- 52 Week High
- BIAF $3.16
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- BIAF 48.21
- PRTG 64.02
- Support Level
- BIAF $0.46
- PRTG $6.75
- Resistance Level
- BIAF $0.58
- PRTG $15.82
- Average True Range (ATR)
- BIAF 0.11
- PRTG 2.15
- MACD
- BIAF -0.01
- PRTG 0.29
- Stochastic Oscillator
- BIAF 8.65
- PRTG 44.60
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.